Evaluation of the Use of Levemir® in Insufficiently Controlled Patients With Type 1 or Type 2 Diabetes

Novo Nordisk A/S4,464 enrolled

Overview

This study conducted in Europe. The aim of this study is to evaluated the use of insulin detemir (Levemir®) in insufficiently controlled patients with type 1 or type 2 diabetes.

Study Type

OBSERVATIONAL

Enrollment

4,464

Conditions

Diabetes Diabetes Mellitus, Type 1 Diabetes Mellitus, Type 2

Interventions

insulin detemirDRUG

Prescribed at the discretion of the physician

Eligibility

Sex: ALL

Medical Language ↔ Plain English

Inclusion Criteria: * Patients with insufficiently controlled type 1 or type 2 diabetes mellitus under their previous therapy

Locations (1)

Unnamed facility

Mainz, Germany

Outcomes

Primary Outcomes

HbA1c (glycaemic haemoglobin)

Fasting plasma glucose (FBG)

Secondary Outcomes

Body weight change

Adverse drug reactions (ADR)

Serious adverse drug reactions (SADR)

Hypoglycaemic episodes

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.